Yes. Dr. Lin is a contributing author to Harry's Cosmeticology (9th Edition), the definitive technical textbook for the cosmetic industry. She authored the clinical chapter titled "Eyelashes: Anatomy and Conditioners for Increasing Length and Fullness/Thickness" (Vol. 2, pp. 480–486).

Yes. MD Lash Factor is the formulation studied in a randomized, double-blind, placebo-controlled clinical trial published in the Journal of Cosmetic and Laser Therapy in 2008 (DOI 10.1080/14764170802054138; PMID 18569264). After four weeks of nightly use, eyelash length increased by 42% to 53% across the active groups compared with 20% for placebo — a statistically significant difference, measured by a blinded technician using a microcaliper. All patients reported an improved appearance in the length of their lashes, and there was also a subjective report of enhanced lash thickness.

Hormonal influences on the hair follicle change significantly throughout a woman's life. During puberty, androgens stimulate terminal hair growth. In reproductive years, cycling estrogen maintains density. Pregnancy extends the Anagen (growth) phase, while the postpartum drop in estrogen leads to Telogen Effluvium (shedding).

• Estrogen: Prolongs the Anagen phase and reduces the resting (Telogen) phase.
• Progesterone: Inhibits 5-alpha reductase, decreasing the conversion of testosterone into DHT.
• Androgens: Can inhibit scalp hair growth while stimulating body hair growth.

Post-menopausal hair loss is primarily driven by estrogen depletion. As estrogen levels fall, there is a relative increase in androgen activity. This imbalance shortens the growth cycle, causing hair to become finer, shorter, and more brittle.

Figure 1: Endocrine Regulation of the Hair Cycle. In menopause, the protective 'Anagen' phase is significantly shortened due to hormonal shifts.

• Follicle Nutrition: Delivering conditioning agents and antioxidants directly to the lash line.
• Clinical Monitoring: Being aware of conditions like Frontal Fibrosing Alopecia (FFA).
• Low-Traction Grooming: Avoiding mechanical stress on brittle, mature hairs.

The lash-line concern in menopause is a shortened Anagen phase and finer, more brittle lash shafts. MD Lash Factor is a nightly conditioning serum whose active ingredient is dechloro ethylcloprostenolamide, a cosmetic-grade prostaglandin analogue, formulated with Thiotaine and other conditioning agents to support the appearance and condition of the lashes. It is the formulation evaluated in our published 2008 clinical trial.

Yes. The active ingredient in MD Lash Factor is dechloro ethylcloprostenolamide, a cosmetic-grade prostaglandin analogue. It is not bimatoprost, not latanoprost, and not a prescription drug. It is the compound evaluated in our published 2008 clinical trial and in the independent ocular safety, dermal irritation and sensitization testing that supports the formulation.

Customers who prefer a formulation without prostaglandin compounds — or who are in a market whose regulations require one — can choose MD Lash Factor Ultima, which is formulated without prostaglandin compounds.

MD Lash Factor contains dechloro ethylcloprostenolamide and is the formulation studied in our 2008 peer-reviewed clinical trial. MD Lash Factor Ultima is formulated without prostaglandin compounds, for customers who prefer that and for markets whose regulations require it. Ultima has been evaluated for safety and tolerance — a four-week ocular safety study under IRB oversight with ophthalmologist supervision, a 50-subject human repeat insult patch test, and an independent European safety assessment under Regulation (EC) No. 1223/2009. Our published efficacy trial was conducted on the original MD Lash Factor formulation, not on Ultima.

Yes. In an independent four-week in-use ocular safety evaluation (n=35) conducted under IRB-approved protocol with ophthalmologist supervision, the test material did not demonstrate a potential for eliciting ophthalmic irritation. The panel included contact lens wearers, non-wearers, and subjects with self-assessed sensitive eyes. No clinically significant change in visual acuity, tear film or intraocular pressure was observed under study conditions. As with any eye-area cosmetic, remove contact lenses before applying and stop use if irritation persists.

Yes — and we would rather show you the numbers than offer a reassurance.

MD Lash Factor has been evaluated in a published randomized, double-blind, placebo-controlled clinical trial and in independent ocular and dermal safety studies. In the published trial, 15 of 34 patients reported mild or minimal irritation. It was transient and typically resolved within a few days of continued use. One patient reported moderate irritation and discontinued. No iris pigmentation change, no darkening of the skin around the eye and no discoloration were observed during the study.

Clinical trial figures tend to run higher than everyday customer reports, because trial participants are asked about symptoms at every visit, while customers usually mention something only when it bothers them. Both numbers are worth knowing, and we would rather publish the higher one.

Reactions reported for cosmetic prostaglandin analogues as a class include temporary redness, swelling, itching, a burning sensation, dry eyes, watering of the eyes, styes, temporary darkening of the skin at the lash line, changes to the fat pad around the eye, and eyelash loss. Reported reactions of this kind typically resolve after stopping use. It is not known whether this product or some other factor caused reactions of this type.

If you experience any of these, stop using the product. If symptoms persist, consult your physician. If this is a concern for you, MD Lash Factor Ultima is formulated without prostaglandin compounds.

MD Lash Factor is applied to the skin along the upper lash line — not into the eye. The supplied applicator is designed to deposit a small amount of product at the lash line, and one stroke per eye is the full dose.

Its ocular tolerance has been examined directly rather than assumed. In an independent four-week in-use study conducted under Institutional Review Board oversight, 35 subjects were examined by a board-certified ophthalmologist. The panel included contact lens wearers, non-wearers, and people with self-assessed sensitive eyes. Examination found no clinically significant change in visual acuity, tear film break-up time or intraocular pressure, and no corneal abnormalities on slit lamp biomicroscopy. Three subjects showed trace conjunctival inflammation, which the investigator judged unrelated to the test material. Under the conditions of that study, the test material did not demonstrate a potential for eliciting ophthalmic irritation.

Intraocular pressure is the endpoint that matters most for this category of product, and it was measured in our study.

No cosmetic is right for everyone. Do not use on damaged or irritated skin, during pregnancy or breastfeeding, or — without speaking to your physician first — if you are being treated for glaucoma or any other eye condition. Apply along the upper lash line only, and stop use if irritation persists.

Most prestige lash conditioners — including MD Lash Factor — are built on cosmetic-grade prostaglandin analogues. Reported effects associated with this class of ingredient, principally from the prescription ophthalmic drugs bimatoprost and latanoprost used at pharmaceutical concentrations, include periorbital skin darkening, iris pigmentation change and periorbital fat atrophy. MD Lash Factor contains neither of those drugs, and our formulation has been evaluated in an independent four-week ocular safety study and in dermal irritation and sensitization testing.

A prostaglandin-free lash serum is one formulated without prostaglandin analogue actives. Some customers prefer them, and some markets — including the European Union and China — restrict prostaglandin analogues in cosmetics. MD Lash Factor Ultima is our prostaglandin-free formulation, developed for exactly these customers and markets. The original MD Lash Factor is not prostaglandin-free; its active is dechloro ethylcloprostenolamide.

Apply MD Lash Factor first to clean, dry skin. Once fully absorbed (approximately 2–3 minutes), apply your retinol. MD Lash Factor was non-sensitizing in independent repeat insult patch testing. If you are using a prescription retinoid around the eye, check with your physician first.

Yes. MD Lash Factor is intended for adult men and women aged 18 and over. It is not intended for use during pregnancy or breastfeeding, or by anyone with an active eye condition, without consulting a physician first.

It depends on the cause. If thinning is due to age, stress, lash extensions, or cosmetic damage, eyelash conditioners like MD Lash Factor can support the appearance of fuller-looking lashes over time.

No. Apply just once daily, at night, to the upper lash line using the included precision applicator. More frequent application does not improve the result and increases the chance of irritation.

Yes. Always apply MD Lash Factor® to clean lashes before other products, and let it dry fully. Many users find they reach for curlers and extensions less often as the appearance of their lashes improves.

Use within 6 months of opening, as with any eye-area cosmetic product.